| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $86,702 | 2 | 100 |
| Carson Seana | EVP, General Counsel | 0 | $0 | 2 | $86,702 | $-86,702 |
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Over the last 12 months, insiders at Bausch Health Companies Inc. have bought $0 and sold $86,702 worth of Bausch Health Companies Inc. stock.
On average, over the past 5 years, insiders at Bausch Health Companies Inc. have bought $19.26M and sold $10.06M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 60,000 shares for transaction amount of $1.45M was made by Miller Steven D (director) on 2021‑11‑30.
| 2024-12-02 | Sale | Carson Seana | EVP, General Counsel | 440 0.0001% | $8.35 | $3,674 | -9.40% | |
| 2024-09-06 | Sale | Carson Seana | EVP, General Counsel | 13,370 0.0036% | $6.21 | $83,028 | +20.29% | |
| 2024-03-04 | Sale | Carson Seana | EVP, General Counsel | 6,313 0.0018% | $9.80 | $61,867 | -20.67% | |
| 2023-12-05 | Sale | Carson Seana | EVP, General Counsel | 220 <0.0001% | $7.38 | $1,624 | +12.55% | |
| 2023-11-06 | Sale | Carson Seana | EVP, General Counsel | 43 <0.0001% | $7.61 | $327 | +2.55% | |
| 2023-09-06 | Sale | Carson Seana | EVP, General Counsel | 6,685 0.0018% | $8.28 | $55,352 | -10.35% | |
| 2023-03-06 | Sale | Carson Seana | EVP, General Counsel | 495 0.0001% | $9.17 | $4,539 | -10.20% | |
| 2023-03-03 | Sale | Carson Seana | EVP, General Counsel | 780 0.0002% | $9.34 | $7,285 | -13.92% | |
| 2023-02-28 | Sale | Carson Seana | EVP, General Counsel | 292 <0.0001% | $9.32 | $2,721 | -14.93% | |
| 2022-04-14 | Sale | Spurr Robert | U.S. President-Pharma Business | 1,595 0.0004% | $22.19 | $35,393 | -65.94% | |
| 2022-03-15 | Sale | Spurr Robert | U.S. President-Pharma Business | 4,846 0.0014% | $22.20 | $107,581 | -65.00% | |
| 2022-03-08 | Sale | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | 3,889 0.0011% | $21.76 | $84,625 | -64.35% | |
| 2022-03-02 | Sale | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | 11,077 0.003% | $23.37 | $258,869 | -68.14% | |
| 2022-03-02 | Sale | Spurr Robert | U.S. President-Pharma Business | 1,595 0.0004% | $23.37 | $37,275 | -68.14% | |
| 2022-03-01 | Sale | Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | 6,338 0.0018% | $23.82 | $150,971 | -67.14% | |
| 2022-02-15 | Sale | Spurr Robert | U.S. President-Pharma Business | 3,251 0.0009% | $25.02 | $81,340 | -69.84% | |
| 2022-01-18 | Sale | Spurr Robert | U.S. President-Pharma Business | 3,251 0.0009% | $26.63 | $86,574 | -70.45% | |
| 2021-11-30 | Miller Steven D | director | 60,000 0.017% | $24.23 | $1.45M | -60.82% | ||
| 2021-08-05 | VON ESCHENBACH ANDREW C. | director | 2,800 0.0008% | $25.94 | $72,632 | -6.04% | ||
| 2021-08-04 | DE SCHUTTER RICHARD U | director | 20,000 0.0056% | $25.01 | $500,246 | -2.62% |
| Carson Seana | EVP, General Counsel | 433066 0.1172% | $1.94M | 0 | 9 | |
| Paulson John | 25839035 6.992% | $115.76M | 5 | 2 | +31.4% | |
| ValueAct Holdings, L.P. | director | 17931594 4.8523% | $80.33M | 19 | 3 | +19.98% |
| Pearson J. Michael | Chief Executive Officer | 1514664 0.4099% | $6.79M | 2 | 1 | +18.52% |
| Morfit G Mason | See Remarks | 1352941 0.3661% | $6.06M | 1 | 0 | +30.3% |
| UBBEN JEFFREY W | director | 1059793 0.2868% | $4.75M | 3 | 1 | +44.4% |
| PAPA JOSEPH C | CHAIRMAN & CEO | 839601 0.2272% | $3.76M | 5 | 0 | +0.47% |
| Rosiello Robert L. | EVP, Chief Financial Officer | 441675 0.1195% | $1.98M | 3 | 0 | <0.0001% |
| DE SCHUTTER RICHARD U | director | 317109 0.0858% | $1.42M | 10 | 0 | +15.65% |
| DE SILVA RAJIV | President and COO | 265217 0.0718% | $1.19M | 1 | 3 | +16.48% |
| Humphries William D. | President, Ortho-Dermatologics | 235035 0.0636% | $1.05M | 1 | 5 | <0.0001% |
| INGRAM ROBERT ALEXANDER | director | 217724 0.0589% | $975,403.52 | 0 | 1 | |
| Herendeen Paul | EVP and CFO | 216866 0.0587% | $971,559.68 | 3 | 0 | +27.32% |
| Schiller Howard Bradley | Chairman and CEO | 182900 0.0495% | $819,392.00 | 8 | 0 | +11.49% |
| ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | 166758 0.0451% | $747,075.84 | 1 | 5 | <0.0001% |
| Provencio Norma Ann | director | 137495 0.0372% | $615,977.60 | 6 | 8 | +18.22% |
| Loberg Philip Walden Jr | EVP, Interim CFO | 137565 0.0372% | $616,291.20 | 1 | 0 | <0.0001% |
| APPIO THOMAS | Pres&Co-Head Bausch&Lomb/Int'l | 128922 0.0349% | $577,570.56 | 1 | 0 | +3.24% |
| Eldessouky Sam | EVP & Chief Financial Officer | 116857 0.0316% | $523,519.36 | 0 | 1 | |
| WECHSLER AMY B | director | 98325 0.0266% | $440,496.00 | 0 | 1 | |
| Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | 93139 0.0252% | $417,262.72 | 0 | 3 | |
| Spurr Robert | U.S. President-Pharma Business | 90506 0.0245% | $405,466.88 | 0 | 5 | |
| Masterson Richard Kevin | Pres. & COO, Valeant Intl. BB | 89524 0.0242% | $401,067.52 | 0 | 1 | |
| Ross Thomas W. Sr. | director | 79242 0.0214% | $355,004.16 | 3 | 0 | <0.0001% |
| Wells William McDowall | director | 75000 0.0203% | $336,000.00 | 0 | 3 | |
| Durham Mark Andrew | SVP Human Resources | 61595 0.0167% | $275,945.60 | 0 | 2 | |
| PAUL LAURENCE E | director | 60459 0.0164% | $270,856.32 | 5 | 0 | +19.25% |
| Miller Steven D | director | 60780 0.0164% | $272,294.40 | 1 | 0 | <0.0001% |
| Hassan Fred | director | 53969 0.0146% | $241,781.12 | 1 | 0 | +22.43% |
| Kornwasser Laizer | EVP, Company Group Chairman | 53582 0.0145% | $240,047.36 | 6 | 0 | +16.39% |
| Chai-Onn Robert Roswell | EVP, CLO, General Counsel | 43187 0.0117% | $193,477.76 | 2 | 6 | +7.18% |
| VON ESCHENBACH ANDREW C. | director | 38647 0.0105% | $173,138.56 | 2 | 0 | <0.0001% |
| Stolz Brian M. | EVP, Administration & CHCO | 32156 0.0087% | $144,058.88 | 7 | 0 | +19.31% |
| Squires Douglas John Paul | director | 29688 0.008% | $133,002.24 | 0 | 1 | |
| STEVENSON KATHARINE BERGHUIS | director | 23098 0.0063% | $103,479.04 | 4 | 0 | +35.79% |
| Segal Lloyd Mitchell | director | 21174 0.0057% | $94,859.52 | 5 | 0 | +36.29% |
| KARABELAS ARGERIS N | director | 20726 0.0056% | $92,852.48 | 1 | 0 | <0.0001% |
| McKenna Mark C. | President, Salix | 20756 0.0056% | $92,986.88 | 0 | 1 | |
| Farmer Ronald Harold | director | 15532 0.0042% | $69,583.36 | 15 | 0 | <0.0001% |
| Mirovsky Pavel | EVP, Pres. & GM Valeant EMENA | 13675 0.0037% | $61,264.00 | 0 | 3 | |
| Whitaker Anne Clem | director | 7500 0.002% | $33,600.00 | 1 | 0 | <0.0001% |
| Chouinard Michel | COO, Biovail Labs. Intl SRL | 2470 0.0007% | $11,065.60 | 0 | 4 | |
| Pershing Square Capital Management, L.P. | See footnote (3) | 0 0% | $0 | 0 | 2 | |
| Fibiger Hans Christian | Chief Scientific Officer | 0 0% | $0 | 0 | 1 | |
| Mayer Christine | SVP, BTA Pharmaceuticals, Inc. | 0 0% | $0 | 0 | 1 | |
| Hall Susan | Global Head of R&D | 0 0% | $0 | 0 | 1 |
Bausch Health Companies Inc. (BHC) | $910,099,463 | 123 | 11.52% | $1.66B |
$187,390,806 | 89 | 12.62% | $823.54M | |
$12,681,496 | 70 | 20.90% | $885.16M | |
$14,599,168 | 59 | 12.79% | $1.28B | |
$23,522,750 | 59 | -6.74% | $6.27B | |
$11,542,910 | 40 | 56.19% | $980.98M | |
$102,493,771 | 40 | 22.98% | $1.21B | |
$21,020,549 | 38 | -2.84% | $11.93B | |
$73,284,153 | 37 | -4.48% | $3.7B | |
$21,068,600 | 35 | 9.64% | $1.19B | |
$12,998,723 | 30 | 3.46% | $3.38B | |
$78,335,024 | 20 | 4.76% | $71.87B | |
$83,406,412 | 19 | 21.96% | $1.83B | |
$2,233,486 | 16 | -3.32% | $9.95B | |
$1,843,996 | 10 | 22.92% | $1.14B | |
$26,633,903 | 9 | 42.23% | $947.23M | |
$141,200 | 8 | 41.74% | $5.2B | |
$514,533 | 5 | 29.61% | $942.41M | |
$32,954,224 | 5 | -0.22% | $18.96B |
| Increased Positions | 101 | +38.7% | 29M | +11.1% |
| Decreased Positions | 100 | -38.31% | 43M | -16.54% |
| New Positions | 36 | New | 7M | New |
| Sold Out Positions | 31 | Sold Out | 12M | Sold Out |
| Total Postitions | 262 | +0.38% | 243M | -5.45% |
| Icahn Carl C | $188,188.00 | 9.38% | 34.72M | 0 | 0% | 2024-12-31 |
| Goldentree Asset Management Lp | $149,267.00 | 7.44% | 27.54M | -2M | -6.31% | 2024-12-31 |
| Paulson & Co. Inc. | $143,300.00 | 7.15% | 26.44M | 0 | 0% | 2024-12-31 |
| National Bank Of Canada /Fi/ | $83,560.00 | 4.17% | 15.42M | -227,279 | -1.45% | 2024-12-31 |
| Healthcare Of Ontario Pension Plan Trust Fund | $70,460.00 | 3.51% | 13M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $63,332.00 | 3.16% | 11.68M | +145,078 | +1.26% | 2024-12-31 |
| Nomura Holdings Inc | $61,490.00 | 3.07% | 11.35M | 0 | 0% | 2024-12-31 |
| Royal Bank Of Canada | $60,641.00 | 3.02% | 11.19M | -6,003 | -0.05% | 2024-12-31 |
| Ing Groep Nv | $40,650.00 | 2.03% | 7.5M | 0 | 0% | 2024-12-31 |
| Mizuho Markets Americas Llc | $37,940.00 | 1.89% | 7M | 0 | 0% | 2024-12-31 |